Strategy for Developing a Stable CHO Cell Line that Produces Large Titers of Trastuzumab Antibody

The current simple workflow ensures strict monoclonality and relatively high production of trastuzumab. This workflow could potentially be implemented in Research and Development (R&D) laboratories, including in developing countries for the production of recombinant monoclonal antibodies in a cost-effective manner.